Glaucoma is a leading cause of worldwide vision loss, affecting tens of millions of individuals. For clinicians involved in the management of glaucoma, awareness of emerging clinical evidence, including actively recruiting clinical trials, is important for evaluating novel therapies and potential advances in treatment strategies.

Each January is Glaucoma Awareness Month, an opportunity for clinicians to review current guidelines and ongoing clinical trials. In recognition of the awareness month, we have a selection of five ongoing, Phase 3 clinical trials for glaucoma that are currently recruiting in the United States.

Quick View Table of Clinical Trials for Glaucoma
Study TitleEstimated EnrollmentStart DateEstimated Completion
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)400October 2025March 2031
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)400October 2025May 2031
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant610June 2025March 2032
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma130February 2025November 2028
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone230September 2023February 2028
Currently Recruiting, Phase 3 Clinical Trials for Glaucoma

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

  • Sponsor: SpyGlass Pharma, Inc.
  • Goal: This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
  • Interventions: Bimatoprost Implant System, SpyGlass IOL, timolol meleate ophthalmic solution, commercial IOL
  • Primary Outcome Measures: Mean IOP reduction from baseline (mmHg); BCDVA 20/40 or better
  • Time Frames: Weeks two and six and month three; month six
  • Study Details
  • Source

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

  • Sponsor: SpyGlass Pharma, Inc.
  • Goal: This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol ophthalmic solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
  • Interventions: Bimatoprost Implant System, SpyGlass IOL, timolol maleate ophthalmic solution, 0.5%, commercial IOL
    Primary Outcome Measures: Mean IOP reduction from baseline (mmHg); BCDVA 20/40 or better
  • Time Frames: Weeks two and six, and month three; month six
  • Study Details
  • Source

Phase 2/​Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

  • Sponsor: Glaukos Corporation
  • Goal: Evaluate the safety and efficacy of the second generation Travoprost Intracameral Implant compared to Timolol Ophthalmic Solution 0.5% administered twice daily in subjects with open-angle glaucoma or ocular hypertension.
  • Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, sham procedure, placebo eye drops
  • Primary Outcome Measures: Intraocular pressure (IOP)
  • Time Frames: Three months
  • Study Details
  • Source

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

  • Sponsor: AbbVie
  • Goal: This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach.
  • Interventions: XEN63 Glaucoma Treatment System
  • Primary Outcome Measures: Percentage of participants with treatment response of achieving ≥20% reduction in intraocular pressure (IOP) from baseline on the same or fewer number of IOP-lowering medications compared to baseline; Number of participants with adverse events (AEs).
  • Time Frame: Month 12; Month 12
  • Study Details
  • Source

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

  • Sponsor: Glaukos Corporation
  • Goal: Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.
  • Interventions: Travoprost Intraocular Implant, sham procedure 1, iStent infinite, sham procedure 2
  • Primary Outcome Measure: Change from baseline in mean diurnal intraocular pressure (IOP)
  • Time Frame: Three months
  • Study Details
  • Source

Related Guidelines:

Sign up for alerts and stay informed on the latest published guidelines.

Copyright © 2026 Guideline Central, all rights reserved.